Acrivon terminates Akoya/Quanterix diagnostic deal; opens internal CLIA lab

Acrivon Therapeutics, Inc.

Mutually terminated OncoSignature Companion Diagnostic Agreement with Akoya (Quanterix) effective Feb 25, 2026.
No financial payments between the parties for termination; transition plan transfers testing procedures and materials to Acrivon.
Acrivon has completed and certified its own internal CLIA laboratory in Watertown, MA.
Acrivon now has full development and commercialization rights to its proprietary ACR-368 OncoSignature test.
Quanterix will continue to support ACR-368 clinical testing for Acrivon's ongoing Phase 2b study during the transition.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Acrivon Therapeutics, Inc. terminated OncoSignature Companion Diagnostic Agreement with Akoya Biosciences, Inc. (a wholly owned subsidiary of Quanterix Corporation) (effective 2026-02-25).

Action: termination
Agreement: collaboration
Counterparty: Akoya Biosciences, Inc. (a wholly owned subsidiary of Quanterix Corporation)
Effective: 2026-02-25

Exact text from the filing

On February 25, 2026, the Company and Akoya Biosciences, (“Akoya”) a wholly owned subsidiary of Quanterix Corporation (“Quanterix”), entered into a Termination and Transition Agreement pursuant to which they have mutually agreed to terminate (the “termination”) the OncoSignature Companion Diagnostic Agreement, dated June 17, 2022, by and between the Company and Akoya.

View on SEC.gov

291 material agreements filed in the last 30 days. Browse all material agreements →

Acrivon Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-085516

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.